Organization | Curie Institute

Curie Institute Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4

Founded: Paris France (1920)

Organization Overview

First Clinical Trial

1999

NCT00004886

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

Institut Curie | Institut Curie - Hopital Rene Huguenin | Institut Curie - Hopital Rene Huguenin - Saint-Cloud - France | INSTITUT CURIE - Hospital | INSTITUT CURIE - Medical Oncology | Institut Curie Paris | Institut Curie, Paris (FR) | Institut Curie - Paris - France | Institut Curie Paris, France | Institut Curie, Paris, France | INSTITUT CURIE, PARIS france | Institut Curie Saint-Cloud | Institut Curie, Saint Cloud | Institut Curie site de Saint Cloud | Institut Curie Site Saint Cloud | institute Curie | Maria Sklodowska-Curie National Research Institute of Oncology | Maria Skłodowska-Curie National Research Institute of Oncology

Active Ingredients

Drugs in Phase 4 Trials (1)

ropivacaine (naropin) (4 trials)

Drugs in Phase 3 Trials (25)

anastrozole (arimidex) (2 trials)

bortezomib (velcade) (1 trial)

cabazitaxel (jevtana kit) (1 trial)

carboplatin (paraplatin) (6 trials)

cetuximab (erbitux) (3 trials)

cisplatin (platinol) (4 trials)

cyclophosphamide (cytoxan) (8 trials)

dexmedetomidine (precedex) (1 trial)

docetaxel (taxotere) (2 trials)

etoposide (vepesid) (5 trials)

exemestane (aromasin) (1 trial)

fludeoxyglucose f-18 (1 trial)

fulvestrant (faslodex) (2 trials)

letrozole (femara) (3 trials)

lomustine (1 trial)

melphalan (alkeran) (4 trials)

morphine (1 trial)

mustophorane (1 trial)

nbtxr3 (1 trial)

rituximab (rituxan) (3 trials)

sodium chloride (1 trial)

tamoxifen (nolvadex) (3 trials)

topotecan (hycamtin) (1 trial)

vincristine (oncovin) (5 trials)

Drugs in Phase 2 Trials (64)

abiraterone (zytiga) (1 trial)

afatinib (gilotrif) (1 trial)

AsiDNA (1 trial)

autologous mononuclear stem cell (1 trial)

bevacizumab (avastin) (5 trials)

bintrafusp alfa (1 trial)

busulfan (myleran) (2 trials)

capecitabine (xeloda) (1 trial)

cladribine (leustatin) (1 trial)

dasatinib (sprycel) (1 trial)

doxorubicin (Doxil) (2 trials)

durvalumab (imfinzi) (4 trials)

emtansine (1 trial)

epirubicin (ellence) (1 trial)

epoetin (Epogen) (1 trial)

erlotinib (tarceva) (1 trial)

everolimus (zortress) (1 trial)

fluorouracil (efudex) (4 trials)

gedatolisib (1 trial)

gemcitabine (gemzar) (1 trial)

hemopoietic stem cell (1 trial)

ibrutinib (imbruvica) (1 trial)

ifosfamide (ifex) (1 trial)

imatinib (gleevec) (1 trial)

interferon alpha-2b (Intron-A) (1 trial)

irinotecan (Camptosar) (2 trials)

lapatinib (tykerb) (1 trial)

lenalidomide (revlimid) (2 trials)

lenvatinib (lenvima) (1 trial)

leucovorin (3 trials)

levoleucovorin (fusilev) (1 trial)

liposomal annamycin (1 trial)

methotrexate (1 trial)

muramyl tripeptide phosphatidyl ethanolamine (1 trial)

naltrexone (revia) (1 trial)

nivolumab (opdivo) (3 trials)

obinutuzumab (gazyva) (1 trial)

olaparib (lynparza) (2 trials)

oleclumab (1 trial)

onapristone (1 trial)

ose2101 (1 trial)

oxaliplatin (eloxatin) (2 trials)

paclitaxel (taxol) (4 trials)

palbociclib (ibrance) (3 trials)

panitumumab (vectibix) (1 trial)

pembrolizumab (keytruda) (2 trials)

peripheral blood hematopoietic cell (1 trial)

pertuzumab (perjeta) (2 trials)

pqr309 (1 trial)

regorafenib (stivarga) (2 trials)

rilotumumab (1 trial)

selinexor (Xpovio) (1 trial)

sorafenib (nexavar) (1 trial)

sunitinib (sutent) (1 trial)

temiri (1 trial)

temozolomide (temodar) (2 trials)

thiotepa (2 trials)

trametinib (mekinist) (1 trial)

trastuzumab (herceptin) (7 trials)

trastuzumab emtansine (kadcyla) (1 trial)

tremelimumab (1 trial)

vemurafenib (zelboraf) (2 trials)

vorinostat (zolinza) (2 trials)

Drugs in Phase 1 Trials (2)

dofequidar (1 trial)

pazopanib (votrient) (1 trial)

Drugs in Other Trials (1)

human fecal microbiota (Reybota) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Adenocarcinoma (Phase 3)

Anus Neoplasms (Phase 2)

Brain Neoplasms (Phase 3)

Breast Neoplasms (Phase 4)

Carcinoma (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Carcinoma, Transitional Cell (Phase 2)

Central Nervous System Neoplasms (Phase 2)

Chordoma (Phase 2)

Colorectal Neoplasms (Phase 2)

Depression (Phase 2)

Esophageal Neoplasms (Phase 2)

Fallopian Tube Neoplasms (Phase 2)

Kidney Neoplasms (Phase 2)

Leukemia (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Lymphoma (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Malnutrition (Phase 2)

Medulloblastoma (Phase 3)

Melanoma (Phase 3)

Meningeal Carcinomatosis (Phase 2)

Meningitis (Phase 2)

Multiple Myeloma (Phase 3)

Myelodysplastic Syndromes (Phase 2)

Myoclonus (Phase 3)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 3)

Neoplasms, Glandular and Epithelial (Phase 2)

Neoplasms, Plasma Cell (Phase 3)

Neoplastic Cells, Circulating (Phase 2)

Nervous System Neoplasms (Phase 2)

Neuroblastoma (Phase 3)

Neurotoxicity Syndromes (Phase 2)

Ocular Motility Disorders (Phase 3)

Opsoclonus-Myoclonus Syndrome (Phase 3)

Osteosarcoma (Phase 2)

Ovarian Neoplasms (Phase 2)

Pain, Postoperative (Phase 4)

Penile Neoplasms (Phase 2)

Peritoneal Neoplasms (Phase 2)

Pleural Effusion (Phase 1)

Pleural Effusion, Malignant (Phase 1)

Preleukemia (Phase 2)

Prostatic Neoplasms (Phase 3)

Recurrence (Phase 3)

Retinal Neoplasms (Phase 2)

Retinoblastoma (Phase 3)

Sarcoma, Ewing (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Stomach Neoplasms (Phase 2)

Syndrome (Phase 3)

Thymoma (Phase 2)

Thymus Neoplasms (Phase 2)

Triple Negative Breast Neoplasms (Phase 1)

Ureteral Neoplasms (Phase 2)

Urinary Bladder Neoplasms (Phase 2)

Uterine Cervical Neoplasms (Phase 2)

Uveal Neoplasms (Phase 3)

Vulvar Neoplasms (Phase 2)

Wounds and Injuries (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 78
# of Trial APIs: 93